BIIB monthly performance report
Monthly BIIB research: returns, drawdown, relative strength, seasonality, and key stats.
BIIB monthly report
—
Key takeaways
- Biogen (BIIB) closed August 2026 at $206.63, up 1.81% for the month and +55.49% over the trailing 12 months.
- Year-to-date, BIIB is +17.41%, outperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading +12.33% versus its 200-day moving average ($183.96), a bullish technical signal.
- Over the past three years, BIIB has underperformed the S&P 500 by −95.45%, with a relative strength index reading of 44.6.
- Win rate over the trailing 39 months stands at 38.5% — 15 positive months versus 24 negative months.
Biogen ended August 2026 at $206.63, posting a monthly return of +1.81%. The S&P 500 returned +3.05% over the same window, leaving relative performance at −1.23%.
The current quarter stands at −2.88% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +12.33% versus the 200-day moving average ($183.96).
Year-to-date, BIIB is +17.41% against SPY +12.89%, a gap of +4.52%. The stock is currently −5.96% below its 52-week high, with maximum 3-year drawdown at −58.64%.
| Period | BIIB | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −0.87% | −0.20% | −0.67% |
| 1 Week | +0.50% | +3.90% | −3.41% |
| 1 Month | +1.81% | +3.05% | −1.23% |
| 3 Months | +9.17% | +7.11% | +2.05% |
| 6 Months |